Human Genome, GSK Dodge Lupus-Drug Suicide Suit

Law360, New York (March 26, 2013, 7:40 PM EDT) -- A Maryland federal judge on Tuesday dismissed a consolidated securities class action accusing Human Genome Sciences Inc. and GlaxoSmithKline PLC of concealing suicide risks associated with lupus drug Benlysta, saying the plaintiffs had failed to show the companies purposefully hid reported suicides from investors.

U.S. District Judge Roger W. Titus said the facts of the case more plausibly showed that the companies had either “acted innocently or, at most, negligently” in not disclosing that that three patients had killed themselves while taking Benlysta during clinical trials,...
To view the full article, register now.